CINECA IRIS Institutional Research Information System

ORLANDI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.429
AS - Asia 3.328
EU - Europa 3.183
SA - Sud America 452
Continente sconosciuto - Info sul continente non disponibili 267
AF - Africa 181
OC - Oceania 10
AN - Antartide 1
Totale 17.851
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.137
SG - Singapore 1.080
IT - Italia 1.053
CN - Cina 888
HK - Hong Kong 490
DE - Germania 469
SE - Svezia 469
BR - Brasile 374
VN - Vietnam 313
CA - Canada 220
GB - Regno Unito 217
BG - Bulgaria 188
FR - Francia 178
FI - Finlandia 135
RU - Federazione Russa 123
TR - Turchia 106
IN - India 99
JP - Giappone 73
UA - Ucraina 73
CI - Costa d'Avorio 67
AT - Austria 59
BD - Bangladesh 43
KR - Corea 36
NL - Olanda 34
PL - Polonia 32
CH - Svizzera 31
BE - Belgio 28
NG - Nigeria 25
ID - Indonesia 23
MX - Messico 22
PK - Pakistan 21
ES - Italia 20
AR - Argentina 19
IQ - Iraq 19
SA - Arabia Saudita 19
SN - Senegal 19
IL - Israele 18
EC - Ecuador 16
MA - Marocco 15
ZA - Sudafrica 15
UZ - Uzbekistan 14
VE - Venezuela 14
CO - Colombia 13
PH - Filippine 13
CZ - Repubblica Ceca 11
SC - Seychelles 11
AU - Australia 9
CR - Costa Rica 9
JO - Giordania 9
DK - Danimarca 8
HN - Honduras 8
JM - Giamaica 8
LT - Lituania 8
EE - Estonia 7
IR - Iran 7
MY - Malesia 7
TT - Trinidad e Tobago 7
CL - Cile 6
IE - Irlanda 6
PS - Palestinian Territory 6
AL - Albania 5
EG - Egitto 5
GR - Grecia 5
NP - Nepal 5
RS - Serbia 5
TW - Taiwan 5
ET - Etiopia 4
GT - Guatemala 4
HU - Ungheria 4
KE - Kenya 4
KH - Cambogia 4
LB - Libano 4
NO - Norvegia 4
PY - Paraguay 4
TH - Thailandia 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
AZ - Azerbaigian 3
BB - Barbados 3
BJ - Benin 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
OM - Oman 3
RO - Romania 3
UY - Uruguay 3
BH - Bahrain 2
HR - Croazia 2
LY - Libia 2
MD - Moldavia 2
NI - Nicaragua 2
PE - Perù 2
PR - Porto Rico 2
PT - Portogallo 2
SV - El Salvador 2
A1 - Anonimo 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
Totale 17.570
Salva come PNG Salva come JPEG
Città #
Ashburn 1.202
Woodbridge 834
Fairfield 612
San Jose 609
Singapore 606
Ann Arbor 603
Dallas 523
Hong Kong 481
Houston 470
Chandler 459
Santa Clara 447
Seattle 308
Wilmington 257
Cambridge 232
Council Bluffs 220
Serra 218
New York 193
Shanghai 193
Sofia 187
Beijing 186
Los Angeles 166
Milan 159
Boardman 116
Munich 102
Ottawa 85
Princeton 85
Ho Chi Minh City 77
Lawrence 75
Lauterbourg 74
Medford 69
Pisa 68
Abidjan 67
Tokyo 65
Jacksonville 64
Dong Ket 60
Des Moines 59
Hanoi 59
Florence 58
London 58
Dearborn 53
Buffalo 51
Izmir 50
Vienna 49
Rome 46
Frankfurt am Main 45
São Paulo 45
Turku 45
Hefei 44
Istanbul 38
Nanjing 38
Phoenix 33
Toronto 33
Helsinki 32
Seoul 32
Columbus 31
Ogden 31
Redondo Beach 30
San Diego 30
Boulder 29
Denver 29
Brussels 28
Düsseldorf 27
The Dalles 27
Atlanta 25
Falls Church 25
Fuzhou 24
Lagos 24
Bremen 23
Montreal 23
Nanchang 23
Orem 23
Warsaw 22
Bern 20
Dakar 19
Marseille 19
Boston 18
Lucca 18
Pune 18
Redwood City 18
Chicago 17
San Francisco 17
Da Nang 16
Brooklyn 15
Stockholm 15
Correggio 14
North Bergen 14
Nürnberg 14
Lancaster 13
Quanzhou 13
Shenyang 13
Rho 12
Hebei 11
Kunming 11
Naples 11
Norwalk 11
Nuremberg 11
Rio de Janeiro 11
Tashkent 11
Vicopisano 11
Baltimore 10
Totale 11.915
Salva come PNG Salva come JPEG
Nome #
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 572
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 442
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 315
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 301
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 292
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 288
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 276
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 274
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 274
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 271
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 270
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 267
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 265
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 265
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 264
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 259
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 258
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 258
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 237
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 233
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 225
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 222
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 221
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 218
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 218
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 212
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 211
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 211
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 205
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy 197
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 197
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 192
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 189
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 189
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 188
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 184
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 184
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 183
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 182
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 181
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 173
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 172
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma 172
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer 171
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 170
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 167
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients: an exploratory retrospective analysis. 165
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions 164
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 164
Pilot study of correlation between single nucleotide polymorphisms (SNPS) of pro-and anti-angiogenic genes and response to bevacizumab (BV) plus chemotherapy (CT) in patients with metastatic breast cancer (MBC) 164
Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation 163
Prevention of capecitabine toxicity using a 5-FU test dose 163
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo 163
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer 163
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 162
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma 160
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report 159
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 159
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors 158
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. 157
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients 156
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients 150
Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue 150
Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer 150
MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA 149
Antiangiogenic drugs in NASH: Evidence of a possible new therapeutic approach 146
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma 145
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells 144
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical and pharmacodynamic evaluation 141
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids 141
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 137
Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases 137
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo 137
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 134
Metronomic Chemotherapy in Elderly Patients 134
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis. 133
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer 131
Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC) 130
Polimorfismi genetici del VEGF e DMLE 130
Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer 129
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 128
null 127
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 126
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma 125
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase 123
null 114
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward 105
Digital Microneedles for Multiplexed Transdermal Sensing via Fluorescent QR Codes 102
null 101
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer 90
null 89
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo 87
Mathematical analysis of metronomic chemotherapy response in metastatic gastrointestinal cancer: identifying critical parameters from clinical data 81
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells 77
null 76
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway 73
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunities 67
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway 58
null 46
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival 46
Totale 17.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.362
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.362
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022811 0 0 0 32 154 154 26 34 53 40 54 264
2022/20231.467 175 223 126 128 158 187 9 104 259 6 80 12
2023/2024850 82 97 93 56 101 167 26 48 18 22 53 87
2024/20252.993 17 114 43 192 302 325 228 126 302 390 331 623
2025/20264.271 285 410 503 323 407 264 630 220 241 368 476 144
2026/20272.082 242 511 570 759 0 0 0 0 0 0 0 0
Totale 17.851